You need JavaScript to view this

Diagnostic and therapeutic perspectives in nuclear medicine: radiolabelled biomolecules; Perspectivas diagnosticas y terapeuticas en medicina nuclear: biomoleculas radiomarcadas

Abstract

From their beginning, the radiopharmaceuticals chemistry has gone to the study of the molecular chemistry. The radiopharmaceuticals are only in their capacity to detect such specific biochemical places as the receivers and the enzymes. With the recent obtaining of the complete structural sequence of the genome, it doesn't fit doubt of the importance that they have acquired the molecular images for the study from the genetic information to the alterations phenotypic in the chemistry of the human body. So, the future of the diagnostic and therapeutic nuclear medicine, practically is based in the study of protein fragments, peptide structures and chains of DNA radiolabelled for the study of the metabolism In vivo. These investigations represent a substantial change in those paradigms of the pharmaceutical development, when using the own organic capacities as source of medications, instead of considering to the organism like a simple assay tube where molecules act, like they are most of the traditional medications. The investigation of new techniques to design complex stable of Tc-99m, Re-188, Lu-177, Y-90 and Dy-166/Ho-l66 with biomolecules that don't alter the specificity and in general the molecular properties of the same ones. it is a topic of world interest in the environment  More>>
Authors:
Ferro F, G; [1]  Murphy, C.A. de; Pedraza L, M; [2]  Melendez A, L [3] 
  1. Gerencia de Aplicaciones Nucleares en la Salud. ININ, 11801 Mexico D.F. (Mexico)
  2. Departamento de Medicina Nuclear. Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico D.F. (Mexico)
  3. Facultad de Medicina, UAEM, 50000 Toluca, Estado de Mexico (Mexico)
Publication Date:
Jul 01, 2003
Product Type:
Conference
Report Number:
INIS-MX-1356
Resource Relation:
Conference: 6. International Conference. 16 National Congress on Solid State Dosimetry, Mexico City (Mexico), 10-12 Sep 2003; Other Information: PBD: 2003
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; AMINO ACIDS; BONE MARROW; DIAGNOSTIC USES; DIAGRAMS; DYSPROSIUM 166; HOLMIUM 166; LABELLED COMPOUNDS; LUTETIUM 177; LYMPHOMAS; NUCLEAR MEDICINE; PEPTIDES; RADIOPHARMACEUTICALS; REACTION KINETICS; RHENIUM 188; SOMATOSTATIN; TECHNETIUM 99; THERAPEUTIC USES; THERMODYNAMIC ACTIVITY; YTTRIUM 90
OSTI ID:
20417929
Research Organizations:
Universidad Autonoma Metropolitana, Unidad Iztapalapa, Mexico D.F. (Mexico)
Country of Origin:
Mexico
Language:
Spanish
Other Identifying Numbers:
Other: ISBN 03-2003-092511210400-01; TRN: MX0300294002744
Availability:
Available from INIS in electronic form
Submitting Site:
MXN
Size:
9 pages
Announcement Date:
Jan 29, 2004

Citation Formats

Ferro F, G, Murphy, C.A. de, Pedraza L, M, and Melendez A, L. Diagnostic and therapeutic perspectives in nuclear medicine: radiolabelled biomolecules; Perspectivas diagnosticas y terapeuticas en medicina nuclear: biomoleculas radiomarcadas. Mexico: N. p., 2003. Web.
Ferro F, G, Murphy, C.A. de, Pedraza L, M, & Melendez A, L. Diagnostic and therapeutic perspectives in nuclear medicine: radiolabelled biomolecules; Perspectivas diagnosticas y terapeuticas en medicina nuclear: biomoleculas radiomarcadas. Mexico.
Ferro F, G, Murphy, C.A. de, Pedraza L, M, and Melendez A, L. 2003. "Diagnostic and therapeutic perspectives in nuclear medicine: radiolabelled biomolecules; Perspectivas diagnosticas y terapeuticas en medicina nuclear: biomoleculas radiomarcadas." Mexico.
@misc{etde_20417929,
title = {Diagnostic and therapeutic perspectives in nuclear medicine: radiolabelled biomolecules; Perspectivas diagnosticas y terapeuticas en medicina nuclear: biomoleculas radiomarcadas}
author = {Ferro F, G, Murphy, C.A. de, Pedraza L, M, and Melendez A, L}
abstractNote = {From their beginning, the radiopharmaceuticals chemistry has gone to the study of the molecular chemistry. The radiopharmaceuticals are only in their capacity to detect such specific biochemical places as the receivers and the enzymes. With the recent obtaining of the complete structural sequence of the genome, it doesn't fit doubt of the importance that they have acquired the molecular images for the study from the genetic information to the alterations phenotypic in the chemistry of the human body. So, the future of the diagnostic and therapeutic nuclear medicine, practically is based in the study of protein fragments, peptide structures and chains of DNA radiolabelled for the study of the metabolism In vivo. These investigations represent a substantial change in those paradigms of the pharmaceutical development, when using the own organic capacities as source of medications, instead of considering to the organism like a simple assay tube where molecules act, like they are most of the traditional medications. The investigation of new techniques to design complex stable of Tc-99m, Re-188, Lu-177, Y-90 and Dy-166/Ho-l66 with biomolecules that don't alter the specificity and in general the molecular properties of the same ones. it is a topic of world interest in the environment of the radiopharmaceutical chemistry. In this work some achievements and perspectives are presented on those main diagnostic and therapeutic radiopharmaceuticals of third generation. (Author)}
place = {Mexico}
year = {2003}
month = {Jul}
}